WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: A

Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Over

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy an

Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe r

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and rai

Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.11 per share, beating th

Arcutis Biotherapeutics NASDAQ: ARQT reported second-quarter 2026 net product revenue of $129.9 mill

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.11 per share which beat the

Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 millio

Medical sector earnings are off to a strong start, and four biotech companies are positioned to pote

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a like

The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 25.8% upside in t

WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq:

WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq:

Biotech stock Arcutis is in a buy zone and Wall Street is looking for the skin-diseases drugmaker to

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Applicat

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Applica

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how e

WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq:

Virtual health platform offers an additional pathway to care for the more than 45 million people in

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque p

ZORYVE cream 0. 3% is the first once-daily, non-steroidal therapy approved for children with plaque

Arcutis Biotherapeutics NASDAQ: ARQT executives said ZORYVE continues to post strong growth and outl

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere

Expert recommendations focused on the diagnosis and management of genital psoriasis across age group

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and ma

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed th

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 month

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety,

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused o

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and lower

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy an

TD Cowen analyst Tyler Van Buren maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and r

HC Wainwright & Co. analyst Douglas Tsao maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and rai

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.13 per share which beat the

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused o

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and rai

Following the termination, Arcutis plans to assume responsibility for sales and promotion of ZORYVE